Sinedore Pharmaceuticals

Sinedore Pharmaceuticals is a UK-based biotechnology company focused on the development of next-generation, non-opioid analgesics for chronic pain management. The company targets specific ion channels, particularly Nav1.7, to inhibit pain signaling at the source without the central nervous system side effects or addictive properties of opioids. Led by experienced biopharma executives, Sinedore is advancing a pipeline of small molecule inhibitors through preclinical studies. Their mission is to address the global crisis of chronic pain and opioid dependency through precision pharmacology. The company leverages deep expertise in ion channel biology to design highly selective modulators that aim to transform the standard of care for patients suffering from neuropathic and chronic pain conditions.